# Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer
Canonical URL: https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer
Ticker: INBX
Company: Inhibrx
Source: Inhibrx
Published: 2026-04-20 21:03 EST
Original Source URL: https://inhibrx.investorroom.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-16 13:00 EST — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-06-15 13:15 EST — [Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma](https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86) — Source: Inhibrx
- 2026-05-14 20:02 EST — [Inhibrx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results) — Source: Inhibrx
- 2026-05-11 12:00 EST — [Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy](https://biopharmsignal.com/news/INBX/inhibrx-reports-interim-phase-2-data-for-inbrx-106-in-first-line-hnscc-initial-results-demonstrate-potential-costimulatory-benefit-over-pd-1-monotherapy) — Source: Inhibrx
- 2026-05-08 20:00 EST — [Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC](https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-inbrx-106-hexagon-study-in-first-line-hnscc) — Source: Inhibrx
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)